Methods of Treatment of Limited Cognitive Impairment
A method for improving or treating a Limited Cognitive Impairment (LCI) comprising administering to a subject a compound of the invention, or a pharmaceutically acceptable salt thereof is described together with related compositions.
1 - 19 . (canceled)
20 . A method of improving and/or treating Limited Cognitive Impairment (LCI) in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof,
wherein
R 1 represents I-azabicyclo[2.2.2]oct-3-yl,
R 2 represents a hydrogen or (C 1 -C 6 )alkyl,
R 3 represents a hydrogen, halogen or (C 1 -C 6 )alkyl,
A represents an oxygen or sulfur, and
Z represents a halogen, formyl, carbamoyl, cyano, trifluoromethyl, trifluoromethoxy, nitro, amino, formamido, acetamido, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkylthio, (C 1 -C 6 )alkylamino, heteroaryl-carbonylamino, arylcarbonylamino, (C 1 -C 4 )alkylsulfonylamino, di(arylsulfonyl)amino, (C 3 -C 6 )cycloalkylcarbonylmethyl or amino(hydroxyimino)methyl.
21 . The method of claim 20 , wherein the patient has been diagnosed with a symptom, condition, or disorder classified as Limited Cognitive Impairment.
22 . The method of claim 20 , wherein the method improves one or more of the following minor impairments: impairment to memory associated with focus and concentration, impairment to working memory, impairment to cognition, impairment to focus, impairment to mental quickness, and impairment to mental clarity.
23 . The method of claim 20 , wherein the method improves cognition in the patient.
24 . The method of claim 20 , wherein the compound of formula (I) is (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide.
25 . The method of claim 24 , wherein the administered therapeutically effective amount is administered at 0.1 to 3.0 mg/day.
26 . The method of claim 24 , wherein the administered therapeutically effective amount is administered at 0.03 to 1.0 mg/day.
27 . The method of claim 24 , wherein the administered therapeutically effective amount is administered at 0.03 to 0.5 mg/day.
28 . The method of claim 24 , wherein the administered therapeutically effective amount is administered at 0.03 to 0.3 mg/day.
29 . The method of claim 24 , wherein the administered therapeutically effective amount is administered at 0.03 to 0.1 mg/day.